VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

T. brucei Subunit p15 Protein Vaccine
Vaccine Information
  • Vaccine Name: T. brucei Subunit p15 Protein Vaccine
  • Target Pathogen: Trypanosoma brucei
  • Target Disease: African trypanosomiasis (African Sleeping Sickness)
  • Vaccine Ontology ID: VO_0011492
  • Type: Subunit vaccine
  • Status: Research
  • MAPP15 gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant: complete Freunds adjuvant
  • Adjuvant: incomplete Freunds adjuvant
  • Immunization Route: Subcutaneous
Host Response

Mouse Response

  • Host Strain: Swiss
  • Vaccination Protocol: Swiss male mice were injected three times subcutaneously on days 1, 7 and 21 with the antigen. Antigen contained 10 μg of native p15 isolated from T. brucei brucei KETRI 2693, recombinant p15 purified from Ad-p15 infected HEK293 cells, partially purified subpellicular microtubules as a positive control (subpellicular fraction >30 kDa), or with PIPES buffer used to purify p15 as a negative control. Vaccinations included complete Freund’s adjuvant on first injection and incomplete Freund’s adjuvant on second and third injections. To test the protective potential of the recombinant viral vaccine, mice were injected intramuscularly (on days 1, 7 and 21) with 2×109 Ad-p15 virus particles or with control Ad-lacZ (Rasooly and Balaban, 2004).
  • Challenge Protocol: Animals were challenged intraperitoneally on day 31 with 500 T. brucei brucei strain SB1 (Rasooly and Balaban, 2004).
  • Efficacy: Vaccination of mice with p15 (native or recombinant) generated up to 100% protection from an otherwise lethal challenge of a heterologous strain of Trypanosoma brucei (Rasooly and Balaban, 2004).
References
Rasooly and Balaban, 2004: Rasooly R, Balaban N. Trypanosome microtubule-associated protein p15 as a vaccine for the prevention of African sleeping sickness. Vaccine. 2004; 22(8); 1007-1015. [PubMed: 15161078].